摘要:
A mobile communications handset (12) is capable of connection through two different networks (2, 27). When it is out of contact with its preferred local wireless access system (27), the handset will seek a hand-over to the cellular network (2), and will become registered as a “roaming” handset currently connected to the cellular network (2). The cellular network (2) reports this location information to the call server (28), as it would to the HLR of any normal visiting handset, so that incoming calls to the PSTN (6) destined for the user (12) can be routed by way of the cellular network. Outgoing calls are handled as conventional cellular telephony calls. When contact with a local wireless access system (27) is re-established, the contact information is passed to the call server 28, which reports to the cellular network (2) that a handover has occurred. An interface between the call server (28) and cellular network (2) is configured such that the call server (28) emulates a base site controller of the cellular network (2). The cellular network therefore operates conventionally, with the handset (12) logged as operating through this quasi-base site controller. However, the cellular system would continue to register the presence of the handset as co-operating with the quasi-base station (28), even though it would have no visibility of most calls being made to and from the handset (12). This avoids the cellular system (2) attempting to seize control of the handset through a normal cellular base station (21).
摘要:
If an attempt by a first user (3) to contact another party (6) fails, a callback server (1) sets a flag (246). The callback server (1) monitors terminals that have such flags set (25) and is arranged to transmit an alert (27) to the calling party (3) when the called party (6) next becomes available. However, if at the time when the called party (6) becomes available, the calling party (3) is himself no longer available, being now switched off or busy, an additional flag (243) in the store (2), indicative of activity by the calling party (3), prevents a callback alert from being generated until the monitoring process (25) can obtain availability indications (263, 266) in respect of both parties (3, 69) simultaneously. Availability may be determined by factors such as available bandwidth or terminal capabilities. A callback may be initiated when a predetermined number of called parties become available to participate in a conference call.
摘要:
The present invention relates generally to methods and compositions for identifying morphogenic protein analogs. In one embodiment, this invention relates to an osteogenic protein reponsive transcription inhibitory element. This invention also relates to the identified morphogenic protein analogs which can mimic the biological effects of morphogenic proteins, particularly those relating to the BMP family such as osteogenic protein (OP-1), on the regulation of gene expression and tissue inductive capabilities.
摘要:
This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
摘要:
The present invention is to a novel process for the preparation of a compound of the formula: ##STR1## wherein p is 0, or 2;Ar is an optionally substituted phenyl or naphtyl; andinter alia R4 is an optionally susbtituted phenyl, naphth-1-yl, naphth-2-yl, or a heteroaryl ring;which process comprises reacting together an aldehyde of the formula:R.sub.4 --CHO;wherein R.sub.4 is as defined above;a compound of the formula:ArS(O)pH;wherein Ar, and p are as defined above;with formamide, an acid catalyst, and optionally a dehydrating agent.
摘要:
The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. Methods of treating tissue degenerative conditions in a mammal using the pharmaceutical compositions are also provided.
摘要:
This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
摘要:
A method of inhibiting the production of interleukin-1 by monocytes in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 4,5-diaryl-2(substituted)imidazole.
摘要:
A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 2-2'-[1,3-propan-2-onediyl-bis(thio)]bis-1H-imidazole or a pharmaceutically acceptable salt thereof.